<VariationArchive RecordType="classified" VariationID="29723" VariationName="NM_006516.4(SLC2A1):c.876_878dup (p.Tyr293_Ser294insTyr)" VariationType="Duplication" Accession="VCV000029723" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-12-30" DateCreated="2017-04-21" MostRecentSubmission="2023-12-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="38678" VariationID="29723">
      <GeneList>
        <Gene Symbol="SLC2A1" FullName="solute carrier family 2 member 1" GeneID="6513" HGNC_ID="HGNC:11005" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1p34.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="42925353" stop="42958868" display_start="42925353" display_stop="42958868" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="43391045" stop="43424846" display_start="43391045" display_stop="43424846" Strand="-" />
          </Location>
          <OMIM>138140</OMIM>
          <Haploinsufficiency last_evaluated="2016-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SLC2A1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2016-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SLC2A1">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_006516.4(SLC2A1):c.876_878dup (p.Tyr293_Ser294insTyr)</Name>
      <CanonicalSPDI>NC_000001.11:42929303:TAATA:TAATAATA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>1p34.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="42929303" stop="42929304" display_start="42929303" display_stop="42929304" variantLength="3" positionVCF="42929303" referenceAlleleVCF="G" alternateAlleleVCF="GTAA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="43394974" stop="43394975" display_start="43394974" display_stop="43394975" variantLength="3" positionVCF="43394974" referenceAlleleVCF="G" alternateAlleleVCF="GTAA" />
      </Location>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1132" sequenceAccession="LRG_1132">
            <Expression>LRG_1132:g.34871_34873dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.43394977_43394979dup" Assembly="GRCh37">
            <Expression>NC_000001.10:g.43394977_43394979dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.42929306_42929308dup" Assembly="GRCh38">
            <Expression>NC_000001.11:g.42929306_42929308dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008232.1" sequenceAccession="NG_008232" sequenceVersion="1" change="g.34871_34873dup">
            <Expression>NG_008232.1:g.34871_34873dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_006516.4" sequenceAccession="NM_006516" sequenceVersion="4" change="c.876_878dup" MANESelect="true">
            <Expression>NM_006516.4:c.876_878dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_006507.2" sequenceAccession="NP_006507" sequenceVersion="2" change="p.Tyr293_Ser294insTyr">
            <Expression>NP_006507.2:p.Tyr293_Ser294insTyr</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="138140.0017" DB="OMIM" />
        <XRef Type="rs" ID="2124448406" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_006516.4(SLC2A1):c.876_878dup (p.Tyr293_Ser294insTyr) AND Childhood onset GLUT1 deficiency syndrome 2" Accession="RCV000022575" Version="30">
        <ClassifiedConditionList TraitSetID="5232">
          <ClassifiedCondition DB="MedGen" ID="C1842534">Childhood onset GLUT1 deficiency syndrome 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2009-11-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2009-11-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-04-21" MostRecentSubmission="2023-12-17">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19901175</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="5232" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1930" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Dystonia 18</ElementValue>
                <XRef ID="Dystonia+18/2414" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paroxysmal exertion-induced dyskinesia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paroxysmal exercise-induced dystonia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PAROXYSMAL EXERCISE-INDUCED DYSKINESIA WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA</ElementValue>
                <XRef Type="MIM" ID="612126" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PAROXYSMAL EXERTION-INDUCED DYSTONIA WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA</ElementValue>
                <XRef Type="MIM" ID="612126" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PED WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA</ElementValue>
                <XRef Type="MIM" ID="612126" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLUT1 deficiency syndrome 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PxMD-SLC2A1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Childhood onset GLUT1 deficiency syndrome 2</ElementValue>
                <XRef ID="MONDO:0012805" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GLUT1DS2</ElementValue>
                <XRef Type="MIM" ID="612126" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">DYT18</ElementValue>
                <XRef Type="MIM" ID="612126" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PED</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS) is now known to be a continuum that includes the classic phenotype as well as paroxysmal exercise-induced dyskinesia and epilepsy (previously known as dystonia 18 [DYT18]) and paroxysmal choreoathetosis with spasticity (previously known as dystonia 9 [DYT9]), atypical childhood absence epilepsy, myoclonic astatic epilepsy, and paroxysmal non-epileptic findings including intermittent ataxia, choreoathetosis, dystonia, and alternating hemiplegia. The classic phenotype is characterized by infantile-onset seizures, delayed neurologic development, acquired microcephaly, and complex movement disorders. Seizures in classic early-onset Glut1 DS begin before age six months. Several seizure types occur: generalized tonic or clonic, focal, myoclonic, atypical absence, atonic, and unclassified. In some infants, apneic episodes and abnormal episodic eye-head movements similar to opsoclonus may precede the onset of seizures. The frequency, severity, and type of seizures vary among affected individuals and are not related to disease severity. Cognitive impairment, ranging from learning disabilities to severe intellectual disability, is typical. The complex movement disorder, characterized by ataxia, dystonia, and chorea, may occur in any combination and may be continuous, paroxysmal, or continual with fluctuations in severity influenced by environmental factors such as fasting or with infectious stress. Symptoms often improve substantially when a ketogenic diet is started.</Attribute>
                <XRef ID="NBK1430" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10541" />
                <XRef ID="10541" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301603</ID>
                <ID Source="BookShelf">NBK1430</ID>
              </Citation>
              <XRef ID="98811" DB="Orphanet" />
              <XRef ID="C1842534" DB="MedGen" />
              <XRef ID="MONDO:0012805" DB="MONDO" />
              <XRef Type="MIM" ID="612126" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="49120" SubmissionDate="2017-03-25" DateLastUpdated="2023-12-17" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="138140.0017_GLUT1 DEFICIENCY SYNDROME 2" title="SLC2A1, 3-BP INS, TAT_GLUT1 DEFICIENCY SYNDROME 2" />
        <ClinVarAccession Accession="SCV000043864" DateUpdated="2023-12-17" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2009-11-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a 7-year-old girl with GLUT1 deficiency syndrome-2 (GLUT1DS2; 612126), Perez-Duenas et al. (2009) identified a heterozygous de novo 3-bp insertion (TAT) in the SLC2A1 gene, resulting in addition of a tyrosine at codon 292 in the extracellular boundary of the seventh transmembrane domain, predicted to impair blood-brain glucose flux. She already had delayed psychomotor development but presented at age 5 years with episodic flaccidity and loss of ambulation. The episodes continued and were accompanied by gait ataxia, dysarthria, dyskinesias, and choreic movements. Milder features included action tremor, upper limb dysmetria, and ataxia. Brain MRI showed moderately severe supratentorial cortico-subcortical atrophy, and EEG showed mild diffuse slowing. CSF glucose was decreased. Institution of a ketogenic diet resulted in clinical improvement of the movement disorder and increased brain growth, although cognitive skills did not improve.</Attribute>
              <Citation>
                <CitationText>Perez-Duenas, B., Prior, C., Ma, Q., Fernandez-Alvarez, E., Setoain, X., Artuch, R., Pascual, J. M. Childhood chorea with cerebral hypotrophy: a treatable GLUT1 energy failure syndrome. Arch. Neurol. 66: 1410-1414, 2009.</CitationText>
              </Citation>
              <XRef DB="OMIM" ID="612126" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC2A1" />
          </GeneList>
          <Name>SLC2A1, 3-BP INS, TAT</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">3-BP INS, TAT</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="138140.0017" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">GLUT1 DEFICIENCY SYNDROME 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="49120" TraitType="Disease" MappingType="Name" MappingValue="GLUT1 DEFICIENCY SYNDROME 2" MappingRef="Preferred">
        <MedGen CUI="C1842534" Name="Childhood onset GLUT1 deficiency syndrome 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

